Research and experimental development on natural sciences and engineering
LYTIX BIOPHARMA ASA
Revenue 2024
NOK 11.1m
Operating profit
NOK −95.9m
Equity
NOK 107.9m
Incorporated
2003
Employees
6
Share capital
NOK 7.7m
Key figures · 2024
Current ratio
3.91
Equity ratio
73.6%
Key figures over time · 2024
| Key figures | 2024 | Trend |
|---|---|---|
| Lønnsomhet | ||
| Operating margin (%%) | -861.3% | |
| Net margin (%%) | -846.6% | |
| Return on assets (%%) | -65.4% | |
| Likviditet | ||
| Current ratio | 3.91 | |
| Working capital | 107.1m | |
| Soliditet | ||
| Equity ratio (%%) | 73.6% | |
| Debt-to-equity ratio | 0.36 | |
Source: Biztrac.no · Data from the Brønnøysund Register Centre and the Norwegian Tax Administration · Last updated 15.06.2026.